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Background: The phase III COntinuous or INtermittent (COIN) trial failed to show non-inferiority of intermittent compared with
continuous chemotherapy for advanced colorectal cancer in overall survival (OS). The present analysis evaluated whether
the derived neutrophil to lymphocyte ratio (dNLR) could predict the effect of intermittent vs continuous chemotherapy on
OS in patients with advanced colorectal cancer.
Methods: A post hoc exploratory analysis of COIN arms A and C was performed. Landmark analysis was conducted on all patients
with available WBC and neutrophils data. The dNLR was calculated using a formula which has previously demonstrated predictive
power in cancer patients: dNLR¼ANC/(WBCANC). A high dNLR was defined using a cut-off value ofX2.22. Derived neutrophil
to lymphocyte ratio was then correlated with clinical outcomes. Survival curves were generated based on dNLR using the Kaplan–
Meier method. Comparison between groups was performed using Cox regression.
Results: A total of 1630 patients were assigned to the continuous (N¼ 815) or intermittent (N¼ 815) arms. There was a strong
association between dNLR level and OS. The median survival times in the ITT population were 18.6 months and 12.5 months for
patients with low and high dNLR, respectively (HR¼ 1.70; 95% CI¼ 1.52–1.90; Po0.001). The estimate of the hazard ratio did not
alter substantially (HR¼ 1.54) after adjusting for treatment, tumour status, number of metastatic sites, alkaline phosphate and
platelet count.
Conclusions: Derived neutrophil to lymphocyte ratio is strongly prognostic for survival in the COIN intermittent vs continuous
treatment arms. Derived neutrophil to lymphocyte ratio does not predict for detrimental survival in patients treated with
intermittent therapy.
The treatment of advanced colorectal cancer has improved
substantially during the past decade with the introduction of new
and more effective drugs and advances in our understanding of the
disease’s molecular biology (Douillard et al., 2013). However, the
balance between improved survival and costs, in terms of toxicity,
quality of life and financial, can be difficult. The COIN trial
(COntinuous or INtermittent) was developed to conclusively
address this issue (Adams et al., 2011). Approximately 1600
patients with advanced colorectal cancer were randomised to
receive intermittent vs continuous systemic therapy with
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oxaliplatin and fluoropyrimidine. Although the trial did not show
non-inferiority of intermittent compared with continuous che-
motherapy for advanced colorectal cancer in terms of overall
survival, a subgroup analysis suggests that patients with normal
baseline platelet counts could gain the benefits of intermittent
chemotherapy without detriment in survival, whereas those with
raised baseline platelet counts have impaired survival and quality
of life with intermittent chemotherapy, and may do better without
a treatment break.
Numerous studies have established that elevated inflammatory
markers, such as C-reactive protein, neutrophil/lymphocyte ratio
(NLR) and platelet-lymphocyte ratio have been associated with
poor outcomes in cancer patients with colorectal cancer (Walsh
et al., 2005; Liu et al., 2010; Proctor et al., 2012). Platelets count
and neutrophil lymphocyte ratio are inexpensive markers of host
inflammation, and may reflect cytokine activation and more
aggressive disease. A recently reported meta-analysis of 100 studies
comprising 40 559 patients found NLR 4 4 was associated with
poorer OS with hazard ratio for OS of 1.81 (95% CI¼ 1.67–1.97;
Po0.001), an effect observed in all disease subgroups, sites,
and stages (Templeton et al., 2014). Lymphocyte count data was
not collected in the COIN trial, however the derived NLR
(dNLR) has been shown to possess similar prognostic value
(Dirican et al., 2014).
The aim of the present correlative analysis was to evaluate
whether dNLR could predict the effect of intermittent vs
continuous first-line oxaliplatin and fluoropyrimidine chemother-
apy on overall survival in patients with advanced colorectal cancer.
MATERIALS AND METHODS
The trial design and eligibility criteria have been reported
previously (Adams et al., 2011). The primary objective of the
phase 3 MRC COIN study was to assess the effect of pre-planned
treatment interruptions in oxaliplatin and fluoropyrimidine
combination chemotherapy on overall survival. A second rando-
misation in the trial assessed the effect of addition of cetuximab to
continuous oxaliplatin and fluoropyrimidine combination chemo
therapy.
After enrolment, patients were randomly assigned (1) to the
control arm of continuous (arm A) or intermittent (arm C)
chemotherapy. In arm A treatment was continued until disease
progression, development of cumulative toxic effects, or patient
choice. Patients on arm C received chemotherapy for 12 weeks,
after which treatment was stopped completely and the patients
were assessed with imaging every 12 weeks. The same chemother-
apy was restarted on progression.
Derived neutrophil/lymphocyte ratio (dNLR) calculation.
White blood cell (WBC) and absolute neutrophil count
(ANC) were obtained at patient enrolment. The dNLR was
calculated using a formula that was previously shown to have
predictive power in cancer patients (Walsh et al., 2005; Dirican
et al., 2014).
Statistical methods. All statistical analyses were performed by the
Cancer Research UK and University College London Cancer Trials
Centre. All randomly assigned patients for whom data on WBC
and ANC in patient enrolment were available were included in
the analysis. A high dNLR was defined using a cut-off value of
2.2, which was the median dNLR.
Associations were assessed using Kaplan–Meier plots and Cox
proportional hazard models. An interaction between dNLR
(o2.22) and treatment allocation was used to assess the difference
in treatment effects between the two trial arms. Models were
adjusted for the a priori factors of treatment arm (standard,
intermittent), tumour status (resected, locally recurrent,
unresected), number of metastatic sites (0 or 1, 2 or more),
CEA at baseline (o100, X100mg l 1), alkaline phosphatase at
baseline (o100, X100U l 1) and platelet count at baseline
(o400 000 ml 1, X400 000 ml 1). Factors were excluded from
the model when they were missing for more than 10%
of the population including CEA. Initial analysis of the association
between dNLR and overall survival was performed on the
ITT population; all comparisons between treatment groups
was performed on both the ITT and the per protocol population,
defined as all patients who reached the point where the continuous
and intermittent strategies diverged, consistent with the
original trial definition. As this was a non-inferiority trial, all
comparisons between the treatment groups are reported with 80%
confidence intervals, with a boundary of 1.162 used to assess non-
inferiority (Adams et al., 2011). Receiver operating characteristic
analysis was performed to calculate area under the curve (AUC)
using one-year survival as the outcome and baseline dNLR as the
test variable.
Statistical analysis was carried out using Stata version 12.1
(College Station, TX, USA).
RESULTS
Population studied. A total of 1630 patients were assigned to the
continuous (N¼ 815) or intermittent (N¼ 815) arms. There was
incomplete data for 32 patients (N¼ 8 for missing dates, N¼ 55 for
missing platelets, N¼ 1313 for missing dNLR) who were excluded,
resulting in a cohort of 1604 patients (accounting for 98.4% of the
total study population). Of these patients, 971 (60.5%) remained on
study beyond 12 weeks and were included in the per protocol
analysis (Table 1).
Prognostic. There was a strong association between dNLR level
and overall survival. The median survival times in the ITT
population were 18.6 months and 12.5 months for patients with
low and high dNLR, respectively (HR¼ 1.70; 95% CI¼ 1.52–1.90;
Po0.001). The estimate of the hazard ratio did not alter
substantially (HR¼ 1.54) after adjusting for treatment, tumour
status, number of metastatic sites, alkaline phosphatase and platelet
count (Figure 1). The AUC was 64.5% and there was a detection
rate for survival of 82.5% and a false positive rate of 63.1%. As a
comparator, the AUC for platelets was 62.8%, and using a value of
400 000 ml 1 to dichotomise baseline platelets there was a
detection rate of 76.8% and a false positive rate of 58.8%. Both
criteria remain modestly prognostic as previously defined (Walter,
2002).
Predictive effect of high dNLR. There was no evidence of a
differential effect of treatment between the two dNLR groups in the
ITT population only (P¼ 0.20). Among patients with low baseline
dNLR, the hazard ratio for treatment allocation was 1.16 (80%
CI¼ 1.00–1.34) compared to 1.21 (80% CI¼ 1.09–1.34) among the
high dNLR group. In the per protocol population (N¼ 971), the
hazard ratios were 1.06 and 1.26 for the low and high dNLR groups
respectively. There was no evidence to support a differential
treatment effect in this population (P¼ 0.26 for interaction
between dNLR group and treatment allocation), nor evidence of
non-inferiority (Figure 2 and Table 2).
As previously reported, a raised platelet count at baseline
(X400 000 ml 1, recorded for 271 (28%) of 978 patients) predicts a
significant survival detriment from intermittent chemotherapy
(P¼ 0.0027 for interaction). Combining platelet count and dNLR
as a single predictive factor was not superior to platelet count alone
(Supplementary Table 1).
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DISCUSSION
We demonstrate that dNLR is prognostic in the COIN intermittent
vs continuous comparison but does not add to the platelet count in
selecting patients who would benefit from continuous rather than
intermittent therapy. Although some cut-off value of X2.2 did
select a population who benefited from continuous treatment, such
an approach lacks robust statistical process and we have reported
Table 1. Population demographics by dNLR
dNLR p 2.2
(N¼805)
dNLR X 2.2
(N¼799)
Treatment
A–Standard chemotherapy 391 (48.6) 408 (51.1)
C–Intermittent chemotherapy 414 (51.4) 391 (48.9)
Age; median (range) 63.8 (18-82) 63.6 (25-87)
Sex
Male 538 (66.8) 499 (62.5)
Female 267 (33.2) 300 (37.5)
WHO performance status
0–Normal activity without restriction 417 (51.8) 320 (40.1)
1–Strenuous activity restricted; can
do light work
348 (43.2) 402 (50.3)
2–Up and about 450% of waking
hours, limited self-care
40 (5.0) 77 (9.6)
Status of primary tumour
Resected 485 (60.2) 364 (45.6)
Local recurrence 40 (5.0) 44 (5.5)
Unresected/unresectable 280 (34.8) 391 (48.9)
Number of metastatic sites
0 5 (0.6) 8 (1.0)
1 295 (36.6) 262 (32.8)
2 326 (40.5) 316 (39.5)
3þ 179 (22.2) 213 (26.7)
Liver-only metastases
No 623 (77.4) 634 (79.3)
Yes 182 (22.6) 165 (20.7)
Platelets
o400000 ml1 633 (78.6) 490 (61.3)
X400000 ml1 172 (21.4) 309 (38.7)
CEA
o100 402 (65.0) 319 (50.2)
X 100 216 (35.0) 316 (49.8)
Missing 187 164
Alkaline phosphatase
o300 715 (88.8) 620 (77.6)
X300 90 (11.2) 179 (22.4)
Mutations of KRAS, NRAF & BRAF
All wild-type 299 (46.9) 293 (47.7)
At least one mutation 338 (53.1) 321 (52.3)
Missing 168 185
Included in per-protocol analysis 519 (64.5) 452 (56.6)
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Figure 1. Prognostic impact of dNLR on overall survival.
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Figure 2. (A) Impact of low dNLR on overall survival. (B) Impact of high
dNLR on overall survival.
Table 2. Hazard ratios and median survival times of ITT and
per protocol populations by dNLRa
Population
Median survival time
(Arm A vs Arm C) HR (80% CI)
P-value for
interaction
ITT
dNLR o2.2
(N¼805)
19.2 vs 18.1 1.04 (0.936–1.163) 0.20
dNLR X2.2
(N¼799)
13.0 vs 11.9 1.21 (1.094–1.335)
Per protocol
dNLR o2.2
(N¼519)
21.8 vs 21.5 1.06 (0.921–1.224) 0.26
dNLR X2.2
(N¼452)
16.6 vs 15.4 1.26 (1.099–1.446)
aAdjusted for tumour status, number of metastases, alkaline phosphate and platelet count.
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an outcome using the median dNLR of 2.2. We also conclude that
the interpretation of dNLR and the platelet count as predictive
factors is more complex than these numerical values would suggest.
A series of studies have proposed that inflammation-based
prognostic systems like neutrophil to lymphocyte ratio and
thrombocytosis are associated with poor survival of subjects with
cancer. A systematic review of 100 studies comprising 40 559
patient with various solid tumours found NLR was associated with
an adverse OS hazard ratio of 1.81 (95% CI¼ 1.67–1.97; Po0.001)
(Templeton et al., 2014), an effect observed in all disease
subgroups, sites, and stages. In the six prospective studies used
in the NLR meta-analysis containing patients with metastatic
colorectal cancer, there were a total of 1817 patients.
The biological mechanism responsible for a higher dNLR requires
further investigation, particularly in the context of clinical studies of
ruxolitinib and the checkpoint inhibitors. A platelet count of 4400
remains the most robust criteria by which to select patients for
intermittent therapy, and this is being investigated in the FOCUS-4
study (http://www.focus4trial.org/). Statistical uncertainties with
respect to biomarker cut-off values continue to generate difficulties
in the interpretation of prognostic and predictive biomarkers.
In conclusion, both dNLR and platelets counts were prognostic
in patients with metastatic colorectal cancer receiving first-line
chemotherapy in randomised phase III COIN trial. A high dNLR
X2.22 and platelets X400 000 ml 1 were associated with shorter
survival. However, in contrast to platelet count, a high dNLR failed
to predict inferiority of intermittent chemotherapy and cannot be
used for clinical decision of which patients can benefit from
chemotherapy-free breaks.
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